THE GLOBAL FUND AND PEPFAR: COMPLEMENTARY APPROACHES, SUCCESSFUL COLLABORATION
Todd SummersArticle Type:
Article Number: 6
ABSTRACT Although they have different strengths and limitations, the Global Fund and PEPFAR have become complementary and interdependent, Todd Summers writes. Together they have produced substantial results in changing the HIV pandemic’s global trajectory, he says. This commentary describes how PEPFAR and the Global Fund work together, and it explains the different approaches adopted by the two entities.
By working closely together, the Global Fund and the (U.S.) President’s Emergency Plan for AIDS Relief (PEPFAR) have supported nearly 20 million people to access life-sustaining antiretroviral (ARV) treatment, reducing dramatically a runaway infectious killer that was destabilizing communities and imperiling economic growth. With different strengths and limitations, the two initiatives have become complementary and interdependent, and together have yielded substantial results in changing the pandemic’s global trajectory. The Global Fund provides support for over 100 countries with a country-driven approach that emphasizes an inclusive process for developing grant proposals and overseeing their implementation. PEPFAR, as its principal bilateral program on HIV, allows the U.S. to engage a more limited set of countries more directly, harnessing the immense technical capacity of a broad range of government agencies and nongovernmental and faith-based partners to scale programs rapidly to prevent and treat the disease. By understanding and harnessing the unique strengths of each, countries can improve their impact and provide an even more compelling case for continued and even expanded financial support for both.
Despite some early skepticism that the Global Fund and PEPFAR could deliver HIV treatment and prevention services at scale in Africa, both organizations continue to demonstrate strong records of performance and dramatic results. The Global Fund estimates that from its founding in 2002 through the end of 2016, it has, in partnership with PEPFAR and others, saved 22 million lives. It also reports that the Global Fund and PEPFAR are together supporting more than 18 million people living with HIV with lifesaving treatment, allowing those individuals to remain productive as well as reducing substantially their risk of passing the virus to others. Table 1 presents the Global Fund’s own results as of the end of 2016, noting that it is impossible to isolate Global Fund results from PEPFAR’s and others given the cooperative nature of the work and the overlap in coverage (e.g. Global Fund will help pay for the purchase of drugs to treat HIV, and PEPFAR will support the doctors, nurses and community workers that get those drugs to people).
Table 1: Global Fund’s end-2016 results for HIV
|People currently receiving ARV therapy||
|HIV-positive pregnant women receiving ARV prophylaxis for prevention of mother-to-child transmission (PMTCT)||
|Counseling and testing encounters||
|Basic care and support services provided to orphans and vulnerable children||
These achievements have contributed to increasing donor confidence in the Global Fund. In its 2016 multilateral aid review, the U.K.’s Department for International Development found, “The successful performance of the Global Fund in this Multilateral Development Review fed directly into our recent decision to increase funding from £800 million to £1.1 billion for the next three years. This will help to save eight million lives.” The Australian government’s review released in 2017 also gave the Global Fund high marks: “The MPA [Multilateral Performance Assessment] confirmed the Global Fund is a strong, responsive development partner for Australia. Evidence of impact is robust…. The MPA recognized the significant reforms undertaken by the Global Fund over its 2012-2016 Strategy period, including on fraud prevention and control. The Global Fund has also greatly improved its strategic leadership and governance, and made financing more predictable through a needs-based allocation methodology.”
Together, the Global Fund and PEPFAR represent about two-thirds of donor support worldwide for HIV prevention, care, and treatment. External support from donors, however, represents only about one-quarter of total funding for HIV, with the rest financed by the governments of affected countries, foundations, businesses and individuals. As a financing mechanism, the Global Fund has strict eligibility requirements based on gross national income and disease burden. In the current grant cycle, the Global Fund is providing grants to more than 100 low- and middle-income countries around the world. PEPFAR supports a more limited set of countries, though there is significant overlap for the highest burden African countries. Based on its FY 2015 expenditures, PEPFAR had 25 countries in which it spent more than $10 million whereas the Global Fund had 42 countries with grants exceeding $10 million.
At headquarters and country levels, PEPFAR and Global Fund teams work together toward joint goals. On a technical level, the two organizations have worked closely to drive data-centric approaches to investments that maximize the benefits of each dollar invested. Table 2, adapted from PEPFAR’s 2016 report to the U.S. Congress, provides examples of how PEPFAR and the Global Fund engage at the governance, programmatic and technical assistance levels.
Table 2: Examples of PEPFAR and Global Fund engagement
|Policy and governance||
PEPFAR and the Global Fund complement each other because they utilize very different approaches that together support both immediate acceleration of HIV programs as well as longer-term, and perhaps more sustainable, development of national technical and financial capacity, and commitment by affected countries.
Table 3 presents a comparison of approaches by PEPFAR and the Global Fund. (Note: There are certainly some variations in the approaches shown.)
Table 3: Comparison of approaches by PEPFAR and the Global Fund
|“Donor-Driven”: COPs, which detail annual plans, budgets and targets, are negotiated with countries but significantly informed by priorities and approaches set by PEPFAR headquarters. This allows PEPFAR to drive a data-centric approach that typically relies heavily on technical support and engagement by U.S. personnel and their international partners.||“Country-driven”: Proposals are developed by CCMs that bring together government, private-sector, faith-based, donors and civil society groups. This fosters buy-in, engagement, and investment by countries that promotes capacity building and sustainability, even if it is typically slower and more encumbered by systemic weaknesses.|
|Annual: COPs are redeveloped every year based on funding levels determined by annual congressional appropriations and subject to often grueling reviews. Annual revisions and retargeting ensures maximum technical efficiency, but inhibits longer-term planning needed by countries (which face decades of financial demands from people needing treatment) and coordination with other donors and partners across varying financial planning years.||Three-year: Countries are provided allocations based on their disease burden and country income levels (GNI per capita). They must “earn” these allocations by submitting technically robust proposals. They can sometimes be eligible for additional amounts based on priorities established by the Global Fund board for specially reserved matching funds (e.g., addressing HIV among adolescent girls and young women). Likewise, allocations can be reduced if countries fail to provide required co-investments (based on country-specific assessments of their financial capacity) or demonstrative inability to manage or invest grant funds effectively.|
|Full package: The U.S. government brings immense technical and logistical capacity, both from U.S. officials based in country and at headquarters, as well as the wide array of nongovernmental partners it supports. This allows the PEPFAR program to engage fully with countries to meet local needs, fill capacity gaps, and deliver direct services and high-quality programs even in areas with weak capacity. However, it does build dependence on these heavy investments and so makes it harder to decrease and eventually eliminate PEPFAR support.||Funding only: The Global Fund is a financing entity, with no mandate to provide technical support to countries. Its staff are all based at its Geneva headquarters, though grant managers travel extensively. Funds and activities are managed by principal recipients (PRs) in country, which often, but not always, are the host government, for example, its Ministry of Health. The Fund relies on PEPFAR and other partners to help countries make the best use of the funds. It also employs an army of oversight groups to monitor performance and ensure funds are used appropriately. This can mean that programs are weaker in countries where partners are weak.|
|Monitored locally: On the ground U.S. personnel, typically including top leadership of the U.S. embassy, as well as PEPFAR’s headquarters staff and the U.S. Global AIDS Coordinator, are heavily involved in the development of the COPs. This allows for more hands-on engagement in the COP development, and situational awareness of how U.S. investments fit with those of other donors and the local government.||Monitored centrally: Global Fund proposals are reviewed by its grant managers, many of whom have significant technical capacity, but they are often pressed for time and are focused on a broad range of risks. Over the last few years, the Global Fund has shifted more of its staff to the highest-burden countries. Technical reviews are provided to the Global Fund board by the Technical Review Panel (TRP). The TRP also has limited time to commit to any one proposal, and may lack the in-country situational awareness to understand fully the local context and merit of individual proposals.|
These approaches have different strengths and limitations, but are inherently complementary and allow the U.S. government to fight HIV more efficiently and effectively. PEPFAR and the Global Fund have been increasing their cooperation and coordination over time to work more seamlessly together. PEPFAR and the Global Fund are ever more interlinked and interdependent, which is evident in the countries in which they jointly operate. Since the Global Fund does not have any on-the-ground staff, it often relies heavily on the PEPFAR team for information and support. Programmatically, investments are tightly coordinated at country-level planning sessions, with the Global Fund, in many instances, providing funds for the drugs that are then used by PEPFAR and country programs to keep patients alive and productive. In some examples, the Global Fund grant provides more than 90% of HIV commodities, while PEPFAR provides the service delivery and TA support.
This interdependence leads to greater success against HIV, but also makes the two entities more vulnerable: Funding cuts or programmatic restrictions (e.g. restricting funds to certain countries or for specific interventions) in one could seriously affect the capacity of the other and lead to shared failure to achieve strategic targets. Countries, other donors and implementing partners will improve their responses to HIV by understanding and responding to the different approaches of the Global Fund and PEPFAR as they both work to bring an end to the HIV pandemic.
This article is adapted from a report Todd Summers wrote for the Center for Strategic and International Studies (CSIS), entitled “The Global Fund and PEPFAR: Complementary, Successful and Under Threat.” The report was published on 1 September 2017 and is available on the CSIS website here.
Todd Summers is a Senior Advisor in the Global Health Policy Center at CSIS. Todd was Chair of the Global Fund’s Strategy, Investment and Impact Committee (now the Strategy Committee) from November 2011 to March 2014. Todd was Vice-Chair of the same committee (then called the Policy and Strategy Committee) from 2008 to 2011.